Arvinas’ Post

Q4 2023 #FDA and #EMA #DrugApprovals reflect numerous advances and expanded indications for agents targeting a range of therapeutic areas https://lnkd.in/enBKBjsm

The Australia and New Zealand Sarcoma Association (ANZSA) are using this July to highlight ‘the importance of ongoing #research, funding and clinical trials to advance patient outcomes in the fight against #sarcoma’. QBiotics Group Limited supports the position of ANZSA in raising awareness for one of Australia’s rarest #cancers. We pay our respects to and advocate for those affected by sarcomas. QBiotics recently announced the completion of recruitment of our Phase IIa human clinical trial in Soft Tissue Sarcoma (STS) where we are investigating the preliminary efficacy of our anticancer intratumoural small molecule, tigilanol tiglate, in patients with advanced and / or metastatic STS. QBiotics hopes to be able to report results of the trial in early Q1 CY2025. Completion of trial recruitment follows tigilanol tiglate being awarded Orphan Drug Designation for the treatment of STS by the United States Food and Drug Administration (FDA) earlier this year. You can read more about the work QBiotics and ANZSA are doing in relation to STS on their respective websites below. QBiotics: https://shorturl.at/ZIxRx ANZSA: https://shorturl.at/ueJTd

💉 In the 8th edition of #DiscoveringOligonucleotides we discuss the process of approval, registration and commercialisation of therapeutic oligos. Keep reading on our blog.⬇️🧬 📝 https://swki.me/8kzqkNq4 #fundedbyCDTI

Digital Opinion Leaders (DOLs) are experts in the disease who share relevant content on digital channels. At Adnexi, we help treatment developers find these DOLs and leverage their influence across the product development cycle. We also wrote this expert white paper on the topic of DOLs. Get it now at: https://buff.ly/41Gnqik #biopharma #kol #dol #adnexi

Adnexi invites you to listen to this Global Genes RareCAST episode that hosts Sandra Shpilberg, our CEO and Co-founder to discuss the role of KOLs, DOLs and influence mapping in drug development and launch strategies. Listen here: https://buff.ly/3NTVJwN #biopharma #rarediseases #kol #dol #adnexi

Adnexi invites you to listen to this Global Genes RareCAST episode that hosts Sandra Shpilberg, our CEO and Co-founder to discuss the role of KOLs, DOLs and influence mapping in drug development and launch strategies. Listen here: https://buff.ly/3NTVJwN #biopharma #rarediseases #kol #dol #adnexi

Meitheal would like to congratulate Xentria on reaching a critical milestone in its quest to solve unmet clinical needs! The European Medicines Agency (EMA) has granted Orphan Drug Designation to Xentria's flagship candidate, XTMAB-16, and the company has enrolled the first US patient in its worldwide study investigating XTMAB-16 as a revolutionary treatment for sarcoidosis. Learn more about these accomplishments and Xentria in today's press release here: https://lnkd.in/gwf_R-bU For more information regarding the exclusive licensing arrangement for XTMAB-16 in North America between Meitheal and Xentria, go here: https://lnkd.in/gD34yNiP. Follow Meitheal as we live out our Corporate Purpose of "Simplifying Access to Life-Changing Medicine for Good."  #BioTech #Innovation #RareDiseases #Xentria #XTMAB16 #EMA #ClinicalTrial #Sarcoidosis #HealthcareInnovation

Digital Opinion Leaders (DOLs) are experts in the disease who share relevant content on digital channels. At Adnexi, we help treatment developers find these DOLs and leverage their influence across the product development cycle. We also wrote this expert white paper on the topic of DOLs. Get it now at: https://buff.ly/41Gnqik #biopharma #kol #dol #adnexi

Digital Opinion Leaders (DOLs) are experts in the disease who share relevant content on digital channels. At Adnexi, we help treatment developers find these DOLs and leverage their influence across the product development cycle. We also wrote this expert white paper on the topic of DOLs. Get it now at: https://buff.ly/41Gnqik #biopharma #kol #dol #adnexi

#SPMNOTES $IMGN $14.945 +1.24. DFAC (dollar average cost) $4.14 (4.11.23). EXIT $26.00. OVERVIEW: M&A noise from Japan in $30 range. Can be Takeda and partners from August 28, 2023 announcement? "Co announced it has entered into an exclusive collaboration with Takeda (TAK) to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. IMGN will receive a one-time, upfront payment and an additional payment upon conversion of US Food and Drug Administration (FDA) accelerated approval of ELAHERE in platinum-resistant ovarian cancer to full approval. ImmunoGen has retained exclusive production rights and will supply product for development and commercial use in Japan. In exchange, Takeda will receive an exclusive license to develop and commercialize ELAHERE in Japan and is responsible for all regulatory filings and obligations."